Proton pump inhibitors (PPI) use has been identified as a risk factor for future exacerbations and accelerated decline in FEV1 in children with cystic fibrosis. The findings, from a Dutch longitudinal observational study involving 545 children with CF aged 5-18 years of age, add to previous evidence linking PPIs to an increased risk of respiratory ...
PPI use linked to lung disease progression in children with CF
By Michael Woodhead
5 Jul 2018